Numerous studies have suggested that hypertension is associated with the onset of proteinuria in patients with various types of cancers treated with bevacizumab, with this association receiving further support from several studies evaluating patients treated with other inhibitors targeting VEGF signaling, including monoclonal antibodies targeting VEGF and small molecules targeting VEGFR [15, 31]. This evidence concerns the gene KDR and cancer.